Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Keith Stewart, A.; Vincent Rajkumar, S.; Α. Dimopoulos, Meletios; Masszi, Tamás; Špıčka, Ivan; Oriol, Albert; Hájek, Roman; Rosiñol, Laura; S. Siegel, David; Mihaylov, Georgi; Goranova‐Marinova, Vesselina; Rajnics, Péter; Suvorov, Aleksandr; Niesvizky, Rubén; Jakubowiak, Andrzej; F. San Miguel, Jesús; Ludwig, Heinz; Wang, Michael; Maisnar, Vladimír; Minařík, Jiří; Bensinger, William; Mateos, María-Victoria; Ben‐Yehuda, Dina; Kukreti, Vishal; J. Zojwalla, Naseem; Tonda, Margaret; Yang, Xinqun; Xing, Biao; Moreau, Philippe; Palumbo, Antonio

doi:10.1056/nejmoa1411321

Public

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Published in New England Journal of Medicine • Dec 6, 2014

Authors:

A. Keith Stewart

S. Vincent Rajkumar

Meletios Α. Dimopoulos

Abstract

BACKGROUND: Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. METHODS: We randomly assigned 792 ...

Subject

Carfilzomib

Lenalidomide

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!